Inovio Pharmaceuticals Inc.

Inovio Pharmaceuticals Inc. is taking immunotherapy to the next level in the fight against cancer and infectious diseases. They are the only immunotherapy company that has reported generating T cells in vivo in high quantity that are fully functional and whose killing capacity correlates with relevant clinical outcomes with a favorable safety profile. With an expanding portfolio of immune therapies, the company is advancing a growing preclinical and clinical stage product pipeline. Partners and collaborators include MedImmune, Roche, The Wistar Institute, University of Pennsylvania, DARPA, GeneOne Life Science, Plumbline Life Sciences, Drexel University, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, and University of Manitoba.

Expert Comments:

Charles Duncan, Piper Jaffray & Co. (5/18/17)
"Inovio Pharmaceuticals Inc.'s INO-3112 can induce a T-cell response in a small group of HPV-associated H&N cancers. We see this as positive proof-of-concept data for the mechanistic rationale underlying Inovio's platform technology, but we appear a long way from late-stage clinical efficacy data in this and other tumor types. . .we expect Medimmune to begin an open-label Phase II study of ‘0457 + durvalumab in 2Q17."

Management Q&A: View From the Top
J. Joseph Kim
Inovio Pharmaceuticals' pipeline of vaccine and immunotherapeutic products is advancing steadily through the phases of development, with a host of milestones anticipated in 2017, including the start of a Phase 3 trial in cervical dysplasia and the initiation of trials with partners in brain cancer and cancers caused by human papillomavirus. In this interview with The Life Sciences Report, Inovio President and CEO, Dr. J. Joseph Kim, walks investors through the promising possibilities, and also provides updates on its vaccines for the Zika, MERS and Ebola viruses.
read more >
Jason McCarthy, Maxim Group (5/11/17)
"The key driver for Inovio Pharmaceuticals Inc., in our view, remains VGX-3100. . .the company announced that Medimmune has initiated a combination study of MEDIO457 (VGX-3100 + IL-12) and durvalumab (PD-L1) in metastatic head and neck cancer. Inovio also initiated a P2 program of VGX-3100 in vulvar precancer. . .Inovio continues to advance multiple immunotherapy studies forward, which should provide incremental catalysts for the stock as data emerges."

Zacks Equity Research (5/11/17)
"Inovio Pharmaceuticals Inc.'s VGX-3100, an HPV immunotherapy, is the most advanced candidate in the company’s pipeline that is being developed for the treatment of HPV-16/18-related high-grade cervical dysplasia. . .in Apr 2017, Inovio has submitted a complete response to the FDA for the initiation of phase III study on VGX-3100 for HPV-related high grade cervical dysplasia, which was placed on clinical hold in Oct 2016. . .the company started a phase II study to evaluate the efficacy of VGX-3100 in women with HPV-related vulvar neoplasia. This is an indication with orphan status potential."

Ram Selvaraju, H.C. Wainwright & Co. (5/11/17)
"Inovio Pharmaceuticals Inc. has submitted a complete response to the FDA, which includes extensive testing and validation data of its Cellectra 5PSP delivery device developed for the Phase 3 study and future commercial use. If the FDA finds the information in this submission satisfactory to lift the clinical hold, Inovio could start the Phase 3 pivotal study of VGX-3100 for the treatment of HPV-16/18-related high grade cervical dysplasia in this quarter. . .VGX-3100 would be the first candidate within the company’s extensive pipeline to enter a pivotal study."

Charles Duncan, Piper Jaffray & Co. (5/11/17)
"Inovio Pharmaceuticals Inc. reported 1Q17 financial results, ending the quarter with $90M in cash. We believe current cash funds the pipeline to mid’18, and see the main value-creating events as initiation of the Phase III in cervical dysplasia and data in HIV and Zika later this year."

Zacks Equity Research (4/12/17)
"Inovio Pharmaceuticals, Inc. recently reported positive preliminary results from the expanded stage of its phase I study, EBOV-001. The study was conducted to evaluate the company's Ebola DNA vaccine, INO-4212. The company has enrolled an additional 125 patients in the study. . .the EBOV-001 study demonstrated robust immune responses with favorable safety profile in expanded clinical study. It showed that 95% of the subjects generated an Ebola-specific antibody immune response with the mean antibody titer superior to those reported from viral vector-based Ebola vaccines. . .the company was awarded a $45 million grant by the Defense Advanced Research Projects Agency in 2015 to lead a collaborative team for the development of multiple treatment and prevention approaches for Ebola."

Inovio's Zika vaccine has demonstrated robust antigen-specific antibody responses in a Phase 1 study with 40 volunteers.
read more >

More Expert Comments

Experts Following This Company

Larry Biegelsen – Wells Fargo Securities
Charles Duncan, Managing Director, Senior Biotechnology Analyst – Piper Jaffray & Co.
Nick Hodge, Founder and president of the Outsider Club – Outsider Club
Jason Kolbert, Senior Analyst – Maxim Group
Jason McCarthy, Analyst – Maxim Group
Ram Selvaraju, Managing Director; Head of Healthcare Equity Research – Rodman & Renshaw

The information provided above is from analysts, newsletters, the company and other contributors.

Inovio Pharmaceuticals Inc. is a sponsor of Streetwise Reports. The company's sponsorship fees pay for Streetwise Reports to create and update this "Investor Summary Page," to which links are placed on Streetwise Reports' websites and newsletters. Streetwise Reports does not accept stock for the payment of fees. See disclaimer for more details.

The company description, investing highlights and catalyst calendar on this page were prepared by the company. The Expert Comments and Experts Following This Company sections of this page are compiled by Streetwise Reports. There may be other information about the company that is not placed on this page. Streetwise Reports does not guarantee the accuracy or thoroughness of the information contained on this page.

The Expert Opinions above are excerpted from third-party sources not affiliated with or controlled by Streetwise Reports. The statements or opinions expressed in the Expert Opinions above are those of the authors indicated, and Streetwise Reports has not verified the accuracy of material excerpted here.

Streetwise Reports does not provide investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security.Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.

Readers should conduct their own research for all information publicly available concerning the company.